Drugs for Osteochondrodysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 16)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Losartan |
Approved |
Phase 2 |
|
114798-26-4 |
3961 |
Synonyms:
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
[<sup>3</sup>H]-losartan
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Cozaar
Cozaar®|DuP 753|MK-954
DuP 753
DUP 89
DuP-753
HGP1405
HGP-1405
|
Hyzaar
Lortaan
LOSARTAN
Losartan monopotassium salt
Losartan potassium
Losartic
MK-954
Monopotassium salt, losartan
Potassium, losartan
Salt, losartan monopotassium
|
|
2 |
|
Angiotensin II |
Approved, Investigational |
Phase 2 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
3 |
|
Valproic acid |
Approved, Investigational |
Phase 2 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
4 |
|
Morphine |
Approved, Investigational |
Phase 2 |
|
57-27-2 |
5288826 |
Synonyms:
(-)-Heroin hydrochloride
(-)-Morphine
(−)-MORPHINE
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5Α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5Α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
ANHYDROUS MORPHINE
Apokyn
Astramorph PF
AVINZA
Chloride, morphine
Contin, MS
D-(-)-Morphine
DEPODUR
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dulcontin
Duramorph
Duramorph PF
Duromorph
Epimorph
Heroin hydrochloride
Heroine hydrochloride
IDS-NM-009
INFUMORPH
KADIAN
l-Morphine
M.O.S
Meconium
M-Eslon
Morfina
Morfina dosa
|
Morphia
Morphin
Morphina
MORPHINE
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
morphine sulfate|Ms Contin®|Oramorph®
Morphinism
Morphinum
Morphitec
Morphium
Moscontin
MS Contin
MS/L
MS/S
MSIR
N02AA01
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
ORAMORPH
Oramorph SR
Ospalivina
Rescudose
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
Statex
Statex Drops
Substitol
Sulfate, morphine
|
|
5 |
|
Anti-Arrhythmia Agents |
|
Phase 2 |
|
|
|
6 |
|
Antihypertensive Agents |
|
Phase 2 |
|
|
|
7 |
|
Angiotensinogen |
|
Phase 2 |
|
|
16133225 |
Synonyms:
Hypertensinogen
Proangiotensin
Renin substrate
Renin substrate tetradecapeptide
|
Renin-substrate
Serpin a8
SERPINA8
Tetradecapeptide, renin substrate
|
|
8 |
|
Angiotensin Receptor Antagonists |
|
Phase 2 |
|
|
|
9 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 2 |
|
|
|
10 |
|
Giapreza |
|
Phase 2 |
|
|
|
11 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
12 |
|
Psychotropic Drugs |
|
Phase 2 |
|
|
|
13 |
|
Anticonvulsants |
|
Phase 2 |
|
|
|
14 |
|
Histone Deacetylase Inhibitors |
|
Phase 2 |
|
|
|
15 |
|
Anesthetics |
|
Phase 2 |
|
|
|
16 |
|
Pharmaceutical Solutions |
|
|
|
|
|
Interventional clinical trials:
(show all 41)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Immunodeficiency in Cartilage-hair Hypoplasia: Correlation With Pulmonary Disease, Infections and Malignancy |
Unknown status |
NCT02383797 |
Phase 4 |
|
2 |
Morquio's Syndrome: a Case Study |
Terminated |
NCT00609440 |
Phase 4 |
|
3 |
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Completed |
NCT01415427 |
Phase 3 |
BMN 110 - Weekly;BMN 110 - Every Other Week |
4 |
A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI |
Unknown status |
NCT03632213 |
Phase 2 |
Losartan;Placebo |
5 |
Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial |
Completed |
NCT01619644 |
Phase 2 |
sodium valproate;Placebo |
6 |
A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Completed |
NCT01515956 |
Phase 2 |
BMN 110 |
7 |
Scleral Buckling for Retinal Detachment Prevention in Genetically Confirmed Stickler Syndrome : a Randomized Controlled Trial |
Not yet recruiting |
NCT04465188 |
Phase 2 |
|
8 |
A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation |
Terminated |
NCT01697319 |
Phase 2 |
BMN 110 |
9 |
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Terminated |
NCT01609062 |
Phase 2 |
BMN 110 |
10 |
A Multicenter, Multinational, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Terminated |
NCT01242111 |
Phase 1, Phase 2 |
BMN 110 |
11 |
Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation: A Phase I Study |
Completed |
NCT00186914 |
Phase 1 |
|
12 |
Identification of New Genes Involved in the Taybi-Linder Syndrome. |
Unknown status |
NCT03222947 |
|
|
13 |
Natural History of Morquio B and Late-Onset GM1 Gangliosidosis |
Unknown status |
NCT04320329 |
|
|
14 |
A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA |
Approved for marketing |
NCT01858103 |
|
BMN 110 |
15 |
Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Hepatic and Neurological Morquio Disease |
Completed |
NCT03872713 |
|
|
16 |
Longitudinal Studies of Brain Structure and Function in MPS Disorders |
Completed |
NCT01870375 |
|
|
17 |
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome Type A and Maroteaux-Lamy Syndrome |
Completed |
NCT01961518 |
|
|
18 |
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease |
Completed |
NCT01707433 |
|
|
19 |
Gait Analysis in Patients With MPS IVA Treated With Enzyme Replacement Therapy |
Completed |
NCT01920828 |
|
|
20 |
Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them? |
Completed |
NCT03150069 |
|
|
21 |
The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPDII). |
Completed |
NCT03139903 |
|
|
22 |
Clinical and Molecular Manifestations of Human Skeletal Dysplasias and Short Stature |
Completed |
NCT00001754 |
|
|
23 |
Psychological Concomitants of Morquio Syndrome |
Completed |
NCT01752296 |
|
|
24 |
Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy |
Completed |
NCT02208661 |
|
|
25 |
Structured Collection of Data Relating to Rare Diseases With Predominantly Skeletal Involvement |
Recruiting |
NCT05247645 |
|
|
26 |
Registry of Patients Diagnosed With Lysosomal Storage Diseases |
Recruiting |
NCT05619900 |
|
|
27 |
Double Osteotomy for Deformity Correction In Pyle Disease: Comparative Study |
Recruiting |
NCT05046977 |
|
|
28 |
Non-invasive Functional Assessment and Pathogenesis of Morquio A (NIFAMA) |
Recruiting |
NCT05284006 |
|
|
29 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168 |
|
|
30 |
Eight At One Stroke: Attention Gangliosidoses A Registry Study for Patients With Gangliosidoses |
Recruiting |
NCT04624789 |
|
|
31 |
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 |
Active, not recruiting |
NCT03548779 |
|
|
32 |
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) |
Active, not recruiting |
NCT02294877 |
|
Vimizim® (elosulfase alfa) |
33 |
Natural History of Atypical Morquio A Disease: a 5-years Prospective Study in a Series of 9 Adult Patients Followed in a Single Expert Center |
Active, not recruiting |
NCT03204370 |
|
Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM] |
34 |
Biomarker for Morquio Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL |
Active, not recruiting |
NCT01457456 |
|
|
35 |
Physical Activity, Motor Competence, Pulmonary Function, and Quality of Life in Children With Severe Spinal Disease |
Enrolling by invitation |
NCT03494829 |
|
|
36 |
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program |
Enrolling by invitation |
NCT05368038 |
|
|
37 |
Identification and Characterization of Bone-related Genetic Variants in Families |
Terminated |
NCT02762318 |
|
|
38 |
A Multicenter, Multinational, Longitudinal Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome) |
Terminated |
NCT00787995 |
|
|
39 |
Unrecognized Mucopolysaccharidosis I, II, IVA, and VI in the Pediatric Rheumatology Population |
Terminated |
NCT01675674 |
|
|
40 |
Discovering New Biomarkers for Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA (MPSIVA) |
Terminated |
NCT01733615 |
|
|
41 |
Dynamic Gait Analysis in Children With Mucopolysaccharidosis Type IVa |
Withdrawn |
NCT02153255 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|